Lunit INSIGHT MMG

by Lunit  · Based in South Korea → — Seamless AI Support for Breast Cancer Detection
Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor
Regulatory Status Disclosed

Overview

Lunit INSIGHT MMG is an AI-powered software designed to assist radiologists in the interpretation of 2D mammograms for earlier and more accurate breast cancer detection. It leverages deep learning technology to automatically detect suspicious areas such as masses, calcifications, distortions, and asymmetries. The software provides malignancy likelihood scores and visually highlights key areas of interest through heatmaps or contour maps, empowering radiologists with enhanced insights during image review.

Designed for streamlined integration with PACS and existing viewer systems, Lunit INSIGHT MMG supports both single- and double-reading workflows, aiming to shorten reading times, reduce cognitive load, and address the shortage of breast imaging specialists in high-volume settings. Clinical studies have demonstrated its ability to improve screening accuracy, especially in dense breasts, reduce false positives, and minimize unnecessary patient callbacks.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered detection of suspicious areas (mass, calcification, distortion, asymmetry)
  • Malignancy likelihood scores and abnormality scores for lesions and breasts
  • Localization of suspicious areas using heatmaps, contour maps, or color/outline
  • Seamless PACS and viewer integration
  • Supports single- and double-reading workflows
  • Reduces reading time and cognitive load for radiologists
  • Improves screening accuracy, particularly in dense breasts
  • Reduces false positives and unnecessary patient callbacks
  • Provides an assessment of breast density (not FDA-cleared for this feature)
  • Supports DICOM GSPS, DICOM Secondary Capture, DICOM SR, and HL7 for data exchange

Use Cases

  • Earlier breast cancer detection in 2D mammograms
  • Assisting radiologists in interpreting complex mammography images
  • Reducing radiologist workload and addressing specialist shortages in high-volume settings
  • Improving diagnostic accuracy for women with dense breasts
  • Triage of normal cases to allow radiologists to focus on suspicious findings
  • Supporting decision-making for BI-RADS category 3 and 4 cases

What Physicians Need to Know

Key Capabilities
Lunit INSIGHT MMG is an AI-powered CADe/x software that automatically detects suspicious areas for breast cancer on mammograms, including masses, calcifications, distortions, and asymmetries. It provides abnormality scores indicating the likelihood of malignancy and generates heatmaps or contour maps for lesion localization. The tool also supports breast density assessment, though this specific feature is not FDA-cleared.
Clinical Utility
This AI solution significantly improves diagnostic accuracy and enhances early breast cancer detection rates, with studies showing up to a 15% increase in detected cancers and an 18% higher accuracy in extremely dense breasts. It reduces radiologist workload and reading time by up to 36%, decreases false positives and unnecessary recalls (11% decrease in recall rates, 94% reduction in false positive marks), and enhances confidence in interpretation. Lunit INSIGHT MMG supports both single and double-reading workflows and can help address radiologist shortages.
Integration Options
Lunit INSIGHT MMG is designed for seamless integration with existing radiology environments, including PACS, RIS, and CIS. It supports standard output formats such as DICOM GSPS, DICOM Secondary Capture, DICOM SR, and HL7. Flexible deployment options include cloud-based, local on dedicated hardware, or locally virtualized (VM, Docker). The solution also integrates with Volpara Scorecardu2122.
Compliance Status
The tool is FDA Cleared (510(k)) in the US (excluding certain features like breast density assessment) and CE Certified (MDR (EU) 2017/745) in the EU. It also holds regulatory clearance in Canada, the UK, Australia, and New Zealand.
Pricing Model
Specific pricing details for Lunit INSIGHT MMG are not publicly disclosed. Lunit generally offers flexible business models, potentially including payment per image (OPEX) or payment per device (CAPEX). Direct inquiry with Lunit is recommended for detailed pricing information.
User Experience
Users report an intuitive and easy-to-understand interface with clear abnormality scores and visual aids like heatmaps. The system highlights key areas of interest, reducing cognitive load and speeding up the reading process. Its seamless integration into existing workflows contributes to a positive user experience, with radiologists reporting increased efficiency and confidence.
Support Quality
Lunit emphasizes a partner-first approach with dedicated technical support and a robust technical support framework to ensure rapid, secure, and stable integration and operation.
Implementation Complexity
The solution is designed for rapid, secure, and stable integration into existing radiology environments with flexible deployment options (cloud, on-premise, virtualized). Successful real-world deployments, including integration into national screening programs, suggest a manageable implementation complexity.
Evidence Base
Lunit INSIGHT MMG boasts a strong evidence base, validated by numerous peer-reviewed publications in prestigious journals such as JAMA Oncology, The Lancet Digital Health, European Radiology, and Radiology Artificial Intelligence. It has been proven in large-scale prospective and retrospective studies to increase cancer detection rates, reduce recall rates, and decrease reading time. Notably, it has been successfully implemented as an independent reader, replacing one radiologist in double-reading settings in some institutions.
Physician Tip

Lunit INSIGHT MMG serves as a powerful auxiliary tool, not a replacement for clinical judgment. Leverage its AI-driven insights, abnormality scores, and lesion localization to enhance your diagnostic accuracy, especially in challenging cases like dense breasts or subtle lesions. The system can significantly reduce your workload and reading time, allowing you to focus on more complex cases and improve overall screening efficiency. Always integrate AI findings with your comprehensive clinical assessment.

Lunit INSIGHT MMG is built for seamless integration into existing radiology workflows. It is compatible with standard PACS, RIS, and CIS systems and supports various DICOM and HL7 output formats. Deployment can be cloud-based, on-premise, or virtualized, offering flexibility to fit diverse IT infrastructures. Strategic partnerships with imaging vendors further facilitate smooth integration.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact vendor — Subscription-based; contact vendor for specific tiers.
DeploymentSeamless integration into existing PACS and viewers; flexible deployment options.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Lunit INSIGHT MMG received FDA 510(k) clearance (K211678) on November 18, 2021. It is cleared as a Computer-Assisted Detection/Diagnosis (CADe/x) software to aid interpreting physicians in the detection, localization, and characterization of suspicious areas for breast cancer on mammograms.
Integrations
EHR Not specified
Specialties Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Lunit INSIGHT MMG

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Lunit
Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
Lunit announced FDA 510(k) clearance for Lunit INSIGHT MMG, making it available for clinical use in US hospitals and medical institutions. The AI solution has shown high accuracy in detecting breast cancer at an earlier stage, as proven by studies published in major journals.
2021-11
AuntMinnie
Lunit highlights Insight MMG clinical results | AuntMinnie
Lunit is highlighting study results published in Nature Communications that validate the effectiveness of its Lunit INSIGHT MMG in South Korea's national breast cancer screening program. The study found that AI-assisted radiologists detected 13.8% more screen-detected breast cancers.
2025-03
Imaging Technology News (ITN)
Study: AI Tool Helps Detect Breast Cancer Earlier, Reduces Radiologists' Workload
Lunit announced findings from two large-scale studies evaluating Lunit INSIGHT MMG, demonstrating its potential to significantly improve breast cancer screening programs. The Norwegian study, published in JAMA Network Open, showed the AI could estimate future breast cancer risk up to 4 to 6 years before it becomes detectable.
2024-10
Lunit
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
Lunit announced that its AI solution for breast cancer, Lunit INSIGHT MMG, has been CE certified, making it commercially available across the European Economic Area. A study in Lancet Digital Health showed that Lunit INSIGHT MMG-aided radiologists had an increase in sensitivity.
2020-06
Sol Radiology
How Lunit AI Helps Catch Breast Cancer Earlier and Improves Patient Care - Sol Radiology
Lunit INSIGHT MMG is an AI tool that acts as a second pair of eyes for radiologists, scanning mammograms and providing a score to highlight suspicious areas. Studies have shown that using Lunit AI with a radiologist can help doctors find 5u201313% more cancers and reduce the chance of missing cancer.
2025-07
MedTech Dive
Study suggests AI could provide second reading of mammograms - MedTech Dive
A prospective study published in Lancet Digital Health found that an AI tool (Lunit INSIGHT MMG) paired with a double reading by one radiologist was as effective at detecting breast cancer as a double reading by two radiologists. Lunit's Insight MMG solution has received 510(k) clearance from the FDA and a CE mark in Europe.
2023-09
Lunit
Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite
Lunit announced the publication of 100 peer-reviewed papers in SCI journals featuring its Lunit INSIGHT suite as of April 2024, with 45 papers specifically on breast cancer with Lunit INSIGHT MMG and Lunit INSIGHT DBT. These publications highlight AI's potential to stand in for traditional methods of medical image analysis.
2024-05
Lunit
Lunit Study in Radiology Highlights Trust Gap Between Radiologists and AI in Breast Cancer Screening
A new study published in Radiology, based on the prospective ScreenTrustCAD trial, highlights how radiologists interact with AI in real-world breast cancer screening. The findings suggest radiologists were less likely to recall patients flagged by AI, even when those cases were more likely to be cancerous, indicating a trust gap.
2025-04

Videos

Product demos, reviews, and walkthroughs for Lunit INSIGHT MMG.

View all on YouTube

Frequently Asked Questions

Lunit INSIGHT MMG integrates into existing PACS and viewer systems, functioning as an AI-powered assistant that highlights suspicious areas on 2D mammograms with heatmaps, contour maps, and abnormality scores. This integration aims to streamline image review, potentially shorten reading times, and support both single and double-reading workflows, ultimately improving diagnostic accuracy and reducing radiologist workload.
Lunit INSIGHT MMG has received FDA 510(k) clearance in the United States and holds a CE Mark under Europe's Medical Device Regulation (MDR). It is also approved for commercial sales in over 35 countries worldwide, including Canada, the UK, Australia, and New Zealand.
While effective, Lunit INSIGHT MMG is an auxiliary tool and not intended to replace a radiologist's comprehensive review. Studies indicate potential for false negatives, particularly in dense breast tissue, non-mammary zones, or with smaller, lower-grade tumors. There can also be a 'trust gap' where radiologists may be less likely to recall cases flagged solely by AI, even if those cases are more likely to be cancerous.
Lunit INSIGHT MMG has demonstrated diagnostic performance comparable to, and in some studies, superior to human readers in detecting breast cancer, outperforming other commercial AI solutions in accuracy. It can serve as an effective 'second pair of eyes' or potentially replace one human reader in a double-reading setting, improving cancer detection rates without increasing recall rates.
Specific pricing for Lunit INSIGHT MMG is typically not publicly disclosed and requires direct contact with the vendor. It is generally offered under a subscription model to healthcare facilities. Some imaging centers may integrate the AI solution without passing additional costs directly to patients.
No, Lunit INSIGHT MMG is designed as a computer-assisted detection and diagnosis (CADe/x) software to *assist* physicians, not replace them. It functions as an auxiliary aid to enhance a radiologist's ability to detect suspicious lesions and should always be used in conjunction with a complete clinical review and professional judgment.
Lunit INSIGHT MMG incorporates privacy features such as robust data handling controls, data minimization, and de-identification options for research purposes. Contractual agreements for data protection, including Business Associate Agreements (BAA) or Data Processing Agreements (DPA), are typically established through commercial agreements to safeguard patient data.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Custom subscription model
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

More from Lunit

Lunit INSIGHT CXR Triage
Lunit
Radiology & Imaging AI
Lunit INSIGHT CXR Triage is an FDA-cleared AI solution that analyzes chest X-ray images to identify and prioritize emergent cases of pleural effusion and pneumothorax, optimizing workflow in critical care settings.
Contact vendor
Lunit INSIGHT DBT
Lunit
Oncology AI
Lunit INSIGHT DBT is an AI-powered software that enhances breast cancer detection in 3D digital breast tomosynthesis (DBT) exams, aiding radiologists with precise lesion identification, classification, and navigation to improve diagnostic accuracy and efficiency.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18

Investors who backed Lunit INSIGHT MMG

Funded through the company that built this tool.

Mirae Asset Venture Investments
Corporate VC T2
Seoul, South Korea
$5M-$25M
Mirae Asset Venture Investments is the venture capital arm of Mirae Asset Financial Group, a major South Korean financial services firm. The…
Digital Health
AI Tool Finder
AI-powered search. Results may not be comprehensive.